Authors
Latest:
The Role of Postmastectomy Radiotherapy in Locally Advanced Breast Cancer After Pathological Complete Response to Neoadjuvant ChemotherapyExperts examine the case of a previously healthy woman, aged 32 years, presented to the oncology clinic with a 6-month history of left-breast tumor, mastalgia, and swollen axillary nodes.
Latest:
Current Treatment of Peripheral T-cell LymphomaThis review article written by Robert Stuver, MD, et al, reviews current and available treatments for peripheral T-cell lymphoma.
Latest:
Lung Cancer Treatment & ScreeningDr. Nabil Rizk, Chief of Thoracic Surgery on increasing participation and accessibility of lung cancer screening.
Latest:
Selinexor: Clinical Pearls for Current and Future Use in R/R MMDr Joseph Mikhael and Dr Hakan Kaya provide advice for community oncologists who use selinexor and discuss the future of selinexor in patients with R/R MM.
Latest:
Reducing Post-Mastectomy Disparities in Breast Cancer Minority PopulationsA study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.
Latest:
Expert Discusses Strategies for Managing BCG Shortage in Bladder CancerConsidering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Latest:
Medical World News® After Hours: Nurse Practitioner Loren Winters Discusses Staying Balanced With Yoga and AyurvedaDuring an After Hours segment of Medical World News®, Loren Winters, MSN, ANP-BC, OCN, spoke about her passion for health and wellness, expressed through yoga instruction and Ayurvedic health coaching.
Latest:
Enfortumab/Pembrolizumab Dosing Schedule ‘Groundbreaking’ in Urothelial CancerNazy Zomorodian, NP, spoke with CancerNetwork® about the unique dosing schedule of enfortumab vedotin plus pembrolizumab following its accelerated approval by the FDA in advanced/metastatic urothelial cancer.
Latest:
Ocular Toxicities of MEK Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysisJing Han, MD, and colleagues examine the prevalence and characteristics of ocular toxicities associated with MEK inhibition.
Latest:
Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative OncologyAuthors Dori Beeler, PhD; Shelley Wang, MD, MPH; and Viraj A. Master, MD, PhD, spoke with CancerNetwork® about a review article on cancer-related fatigue published in the journal ONCOLOGY®.
Latest:
Closing Remarks on the Future of Treating HER2+ Metastatic Breast CancerThought leaders in breast oncology share closing remarks about the future management of HER2+ BC with brain metastases with key insights on unmet needs and evolving treatment approaches.
Latest:
Cross Q&A: Isa + KD in Relapsed/Refractory MM and Biochemical vs Clinical ProgressionIn the final cross Q&A session from the multiple myeloma module, panelists discuss implications of IKEMA and consider the importance of biochemical versus clinical progression.
Latest:
Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative OncologyAuthors Dori Beeler, PhD; Shelley Wang, MD, MPH; and Viraj A. Master, MD, PhD, spoke with CancerNetwork® about a review article on cancer-related fatigue published in the journal ONCOLOGY®.
Latest:
Expert Commentary on the Product Profile of Lazertinib in NSCLCJenan Dailey, PharmD, BCAP, spoke about the approval of lazertinib plus amivantamab as first-line treatment for patients with locally advanced or metastatic NSCLC.
Latest:
Current Treatment of Peripheral T-cell LymphomaThis review article written by Robert Stuver, MD, et al, reviews current and available treatments for peripheral T-cell lymphoma.
Latest:
NALIRIFOX In Practice: Treatment Strategies for Patients With mPDACPanelists discuss how dose reductions in the NAPOLI-3 trial paradoxically led to improved survival outcomes (12.6 months for nanoliposomal irinotecan reductions and 13.5 months for oxaliplatin reductions versus shorter survival with full doses), supporting their clinical approach of maintaining patients on tolerable doses for longer treatment duration rather than pursuing maximum dose intensity.
